drugset
drugset / Trial / NCT02234999

Radiolabeled Study of CC-122 in Healthy Subjects

NCT02234999 ↗

Phase 1 Completed 6 enrolled Celgene Corporation
NaSingle-groupOther

Summary

To evaluate the metabolism and excretion of \[14C\]-CC-122 in healthy male subjects

Timeline

Start
2014-09-23
Primary completion
2014-10-08
Completion
2014-10-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Avadomide Other / unclassified 3 mg Oral

Indications

No indication recorded.